IMMUNITYBIO, INC. (IBRX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Win.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
47/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
LoseIBRX / S&P 14.15% / 15.20% |
WinIBRX / S&P 192.92% / 15.00% |
WinIBRX / S&P 102.08% / 50.40% |
| 2026-Q13/3 |
WinIBRX / S&P 287.37% / -4.33% |
WinIBRX / S&P 351.53% / 11.30% |
WinIBRX / S&P 46.55% / 27.70% |
| 2025-Q41/3 |
LoseIBRX / S&P -19.51% / 2.65% |
WinIBRX / S&P 668.31% / 9.00% |
LoseIBRX / S&P -39.68% / 13.40% |
| 2025-Q31/3 |
LoseIBRX / S&P -6.82% / 8.12% |
WinIBRX / S&P 1025.95% / 4.61% |
LoseIBRX / S&P -55.43% / 13.45% |
| 2025-Q21/3 |
LoseIBRX / S&P -12.29% / 10.94% |
WinIBRX / S&P 4227.22% / 4.83% |
LoseIBRX / S&P -50.52% / 10.63% |
| 2025-Q12/3 |
WinIBRX / S&P 17.58% / -4.27% |
WinIBRX / S&P 10238.41% / 4.98% |
LoseIBRX / S&P -46.79% / 10.57% |
| 2024-Q41/3 |
LoseIBRX / S&P -31.18% / 2.41% |
WinIBRX / S&P 2270.58% / 5.25% |
LoseIBRX / S&P -45.69% / 6.15% |
| 2024-Q31/3 |
LoseIBRX / S&P -41.14% / 5.89% |
WinIBRX / S&P 1218.71% / 5.89% |
LoseIBRX / S&P -12.38% / 6.11% |
| 2024-Q22/3 |
WinIBRX / S&P 17.69% / 4.28% |
WinIBRX / S&P 120.95% / 5.38% |
LoseIBRX / S&P -14.91% / 5.12% |
| 2024-Q10/3 |
LoseIBRX / S&P 6.97% / 10.56% |
LoseIBRX / S&P -48.46% / 5.71% |
LoseIBRX / S&P 2.83% / 5.59% |
| 2023-Q43/3 |
WinIBRX / S&P 197.04% / 11.69% |
WinIBRX / S&P 159.17% / 6.81% |
WinIBRX / S&P 10.48% / 7.78% |
| 2023-Q31/3 |
LoseIBRX / S&P -39.21% / -3.27% |
LoseIBRX / S&P -0.18% / 7.52% |
WinIBRX / S&P 3.96% / -5.03% |
| 2023-Q23/3 |
WinIBRX / S&P 52.75% / 8.74% |
WinIBRX / S&P 17.23% / 9.50% |
WinIBRX / S&P 20.00% / -8.57% |
| 2023-Q11/3 |
LoseIBRX / S&P -64.10% / 7.50% |
LoseIBRX / S&P -27.56% / 10.77% |
WinIBRX / S&P 12.77% / -15.69% |
| 2022-Q41/3 |
LoseIBRX / S&P 2.01% / 7.56% |
LoseIBRX / S&P -74.30% / 11.88% |
WinIBRX / S&P 17.98% / -17.99% |
| 2022-Q33/3 |
WinIBRX / S&P 33.60% / -4.88% |
WinIBRX / S&P 40.30% / 13.47% |
WinIBRX / S&P 20.24% / -1.41% |
| 2022-Q21/3 |
LoseIBRX / S&P -33.69% / -16.10% |
LoseIBRX / S&P 4.77% / 13.71% |
WinIBRX / S&P 20.25% / 11.04% |
| 2022-Q11/3 |
LoseIBRX / S&P -7.73% / -4.60% |
WinIBRX / S&P 39.72% / 15.97% |
LoseIBRX / S&P IBRX unavailable / 42.23% |
| 2021-Q41/3 |
LoseIBRX / S&P -37.58% / 11.03% |
WinIBRX / S&P 54.38% / 15.00% |
LoseIBRX / S&P IBRX unavailable / 96.40% |
| 2021-Q30/3 |
LoseIBRX / S&P -31.79% / 0.58% |
LoseIBRX / S&P -86.40% / 10.77% |
LoseIBRX / S&P IBRX unavailable / 69.42% |
| 2021-Q20/3 |
LoseIBRX / S&P -39.85% / 8.55% |
LoseIBRX / S&P -82.67% / 6.58% |
LoseIBRX / S&P IBRX unavailable / 51.81% |
| 2021-Q11/3 |
WinIBRX / S&P 78.09% / 6.17% |
LoseIBRX / S&P -75.49% / -1.06% |
LoseIBRX / S&P IBRX unavailable / 7.39% |
| 2020-Q41/3 |
WinIBRX / S&P 92.21% / 12.15% |
LoseIBRX / S&P -72.52% / -3.72% |
LoseIBRX / S&P IBRX unavailable / -33.42% |
| 2020-Q31/3 |
LoseIBRX / S&P -43.53% / 8.93% |
WinIBRX / S&P 7021.95% / -2.04% |
LoseIBRX / S&P IBRX unavailable / -27.10% |
| 2020-Q22/3 |
WinIBRX / S&P 326.39% / 20.54% |
WinIBRX / S&P 4535.00% / -0.46% |
LoseIBRX / S&P IBRX unavailable / -27.11% |
| 2020-Q11/3 |
LoseIBRX / S&P -24.01% / -19.60% |
WinIBRX / S&P 4925.53% / 3.47% |
LoseIBRX / S&P IBRX unavailable / -14.75% |
| 2019-Q42/3 |
WinIBRX / S&P 210.66% / 9.07% |
WinIBRX / S&P 4585.11% / 5.36% |
LoseIBRX / S&P IBRX unavailable / 2.99% |
| 2019-Q31/3 |
WinIBRX / S&P 19.61% / 1.70% |
LoseIBRX / S&P -21.15% / 5.02% |
LoseIBRX / S&P IBRX unavailable / 0.21% |
| 2019-Q21/3 |
LoseIBRX / S&P -35.44% / 4.30% |
WinIBRX / S&P 106.90% / 6.64% |
LoseIBRX / S&P IBRX unavailable / 8.65% |
| 2019-Q12/3 |
WinIBRX / S&P 36.21% / 13.65% |
WinIBRX / S&P 20.51% / 8.12% |
LoseIBRX / S&P IBRX unavailable / 14.29% |
| 2018-Q40/3 |
LoseIBRX / S&P -68.65% / -13.52% |
LoseIBRX / S&P 4.44% / 9.05% |
LoseIBRX / S&P IBRX unavailable / 18.23% |
| 2018-Q32/3 |
WinIBRX / S&P 20.92% / 7.71% |
WinIBRX / S&P 10.64% / 10.21% |
LoseIBRX / S&P IBRX unavailable / 19.06% |
| 2018-Q20/3 |
LoseIBRX / S&P -21.34% / 3.43% |
LoseIBRX / S&P -43.14% / 9.03% |
LoseIBRX / S&P IBRX unavailable / 14.46% |
| 2018-Q10/3 |
LoseIBRX / S&P -13.36% / -0.76% |
LoseIBRX / S&P -20.41% / 7.68% |
LoseIBRX / S&P IBRX unavailable / 12.46% |
| 2017-Q40/3 |
LoseIBRX / S&P -18.07% / 6.64% |
LoseIBRX / S&P 2.27% / 7.03% |
LoseIBRX / S&P IBRX unavailable / 13.82% |
| 2017-Q31/3 |
LoseIBRX / S&P -27.80% / 4.48% |
WinIBRX / S&P 6.82% / 5.68% |
LoseIBRX / S&P IBRX unavailable / 17.57% |
| 2017-Q22/3 |
WinIBRX / S&P 113.80% / 3.09% |
WinIBRX / S&P 21.43% / 4.83% |
LoseIBRX / S&P IBRX unavailable / 17.74% |
| 2017-Q10/3 |
LoseIBRX / S&P -37.94% / 6.07% |
LoseIBRX / S&P -59.50% / 3.67% |
LoseIBRX / S&P IBRX unavailable / 13.32% |
| 2016-Q40/3 |
LoseIBRX / S&P -26.48% / 3.82% |
LoseIBRX / S&P -81.28% / 2.09% |
LoseIBRX / S&P IBRX unavailable / 7.05% |
| 2016-Q31/3 |
WinIBRX / S&P 25.08% / 3.85% |
LoseIBRX / S&P -86.21% / 0.20% |
LoseIBRX / S&P IBRX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | IBRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 258.97% | 20.78% |
| Annualized return | 258.97% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | IBRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -28.81% | 83.14% |
| Annualized return | -6.57% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | IBRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 4.48% | 319.30% |
| Annualized return | 0.44% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |